高血壓治療的進展(已改無錯字)
2022-11-10 05:22:27 本頁面
【正文】 blockers + ?blockers Accelerated HT ?blockers + ACEinhibitors Hypertensives: post MI(sec. Prevention) CHD, CHF Caantagonist + ?blockers HT + CHD Drugs Potential use Caantagonist + ACEinhibitors HT + nephropathy, CHD or atherosclerosis Caantagonists + AT1blockers HT + nephropathy, CHD or atherosclerosis (?) ACEinhibitors + AT1blockers HT + nephropathy ACEinhibitors + imidazoline(I1)receptor agonist Patients with activated RAAS and SNS Diuretics + ?blockers + Ca antagonists Accelerated HT Diuretics + Ca antagonists + ACEinhibitors Accelerated HT ISH, HT + diabetes mellitus Diuretics + Ca antagonists + AT1antagonists HT + DM or ISH ACEinhibitors + ?1blockers + imidazoline(I1)receptor agonist HT + DM. Metabolic syndrome When β –B contraindicated ACEinhibitors + Ca antagonists + ?blockers HT + CHD 聯(lián)合用藥的劑量？ ? 近來只用雙氫克尿塞普通劑量的1/4（ ）或鈉催離普通劑量的1/4（ ） 低劑量聯(lián)合用藥的弊端 ? 劑量無法調(diào)節(jié) ? 降壓藥的有效劑量與中毒劑量并不接近 ，
教學課件相關(guān)推薦
鄂ICP備17016276號-1